Clinical Impact of New HIV Data From the 2016 Co-morbidities and Adverse Drug Reactions Workshop
Source: 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV*

Module

In this Expert Analysis, Todd T. Brown, MD, PhD, and Jordan E. Lake, MD, MSc, provide an in-depth discussion of the most clinically relevant new data on the management of patients with HIV infection presented at the Co-morbidities and Adverse Drug Reactions workshop in New York, New York.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply data from studies of antiretroviral agents used to prevent HIV infection
  • Devise management strategies based on the results of recent clinical studies of antiretroviral agents in treatment-naive and treatment-experienced patients
  • Integrate best practices for the management of adverse events associated with HIV, antiretroviral therapy, and comorbidities

Topics covered include:

  • Introduction
  • Bone Health
  • Cardiovascular Health
  • Assessment of Fat
  • Aging
 

Faculty

  • Todd T. Brown
    MD, PhD
    Jordan E. Lake
    MD, MSc

Credit Information

  • Release Date:
    December 16, 2016
  • Expiration Date:
    December 15, 2017
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Todd T. Brown, MD, PhD


Professor of Medicine and Epidemiology
Division of Endocrinology, Diabetes and Metabolism
Johns Hopkins University
Baltimore, Maryland

Todd T. Brown, MD, PhD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, EMD Serono, Gilead Sciences, Merck, and Theratechnologies.
 

Jordan E. Lake, MD, MSc


Associate Professor
Division of Infectious Diseases
McGovern School of Medicine
University of Texas Health Science Center at Houston
Houston, Texas

Jordan E. Lake, MD, MSc, has disclosed that she has received consulting fees from Gilead Sciences and GlaxoSmithKline.
 

Staff

Jennifer M. Blanchette, PhD


Managing Editor

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
 

Rachael M. Andrie, PhD


Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
 

Carolyn Skowronski, 


Carolyn Skowronski, PharmD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

Edward King, MA


Executive Vice President

Edward King, MA, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Database Administrative Secretary, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the care of patients at risk of or infected with HIV.


Goal

The goal of this activity is to improve participants’ competence in translating the most clinically significant data from an important scientific meeting into practical management strategies for individuals at risk of or infected with HIV.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply data from studies of antiretroviral agents used to prevent HIV infection
  • Devise management strategies based on the results of recent clinical studies of antiretroviral agents in treatment-naive and treatment-experienced patients
  • Integrate best practices for the management of adverse events associated with HIV, antiretroviral therapy, and comorbidities
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from Bristol-Myers Squibb.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 16, 2016, through December 15, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

  • Selecting First-line Antiretroviral Therapy in Older Patients: New Data, New Options, Key Considerations

    Giovanni Guaraldi MD - 12/16/2015    2 comments / Last Comment: 2/10/2016
    The management of ART in patients aging with HIV requires clinicians to maintain a detailed knowledge of physical and psychological patient health in order to tailor the most appropriate ART regimen.
  • The Imperative for Women-Initiated HIV Prevention Technologies

    Quarraisha Abdool Karim PhD - 7/8/2016    1 comment / Last Comment: 7/11/2016
    Professor Quarraisha Abdool Karim, PhD, introduces her take on one of the key challenges for women at risk of HIV infection and evolving strategies for prevention. At an upcoming symposium in Durban, Catherine Hankins, MD, PhD, FRCPC, CM, and a multidisciplinary panel of experts will continue this discussion by providing their perspectives on 3 global challenges to treatment and prevention of HIV in women.
  • ART in Older Patients: How I Manage Drug–Drug Interactions With Concomitant Medications

    Anton L. Pozniak MD, FRCP - 10/20/2015    16 comments / Last Comment: 5/10/2016
    As our patients age, they experience metabolic changes and more frequently develop conditions such as bone mineral density loss, cardiovascular disease, diabetes, and malignancies, all of which will affect the choice of first-line ART.
  • Why ART Trials Specific to Women Are Important

    Kathleen E. Squires MD - 9/28/2016    2 comments / Last Comment: 10/19/2016
    Although almost one half of new HIV infections worldwide occur in women, to date, clinical trials for FDA-approved ART regimens have largely been conducted in men. Here is my take on why women-specific ART trials are important.
  • Switch Strategies in Virologically Suppressed Patients: My Take on New Data From Recent Scientific Meetings

    Anton L. Pozniak MD, FRCP - 1/22/2016    15 comments / Last Comment: 11/14/2016
    Several recent studies have highlighted new approaches to ART switching. Some may expand our options for optimizing long-term virologic suppression in our patients; each should be scrutinized carefully before incorporating into practice.